DC-CIK细胞免疫治疗联合化疗对晚期卵巢癌患者疗效及血清CD133、DDX4水平的影响

目的:探讨DC-CIK细胞免疫治疗联合化疗治疗晚期卵巢癌的临床疗效以及对患者血清CD133、DDX4水平的影响。方法:将60例晚期卵巢癌患者随机分为观察组(30例)和对照组(30例),对照组仅接受常规化疗,观察组采用化疗联合DC-CIK细胞免疫治疗。比较两组患者的免疫功能、治疗效果、不良反应以及血清CD133、DDX4水平在治疗前后的变化情况。结果:观察组的客观缓解率(80.0%)高于对照组(50.0%);在治疗后和6个月随访时观察组CD3+、CD3+CD4+、CD4+/CD8+以及NK细胞的比值均高于对照组,CD4+CD25+、CD133、DDX4水平均低于对照组;且治疗前、治疗后、6个月随访后自身比较CD3+CD4+、CD4+/CD8+、NK细胞比值均明显升高,CD133、DDX4水平均明显降低(均P<0.05);治疗后与6个月随访后免疫功能指标两组无差异(P>0.05),骨髓抑制和肝功能损害的发生率观察组低于对照组(P<0.05)。结论:应用DC-CIK细胞免疫治疗联合化疗治疗晚期卵巢癌患者可提高临床治疗效果,增强患者免疫能力,更大幅度降低血清CD133、DDX4水平,减少不良反应的发生,值得临床探索应用。

Effect of DC-CIK immune-cell therapy combined with chemotherapy on treatment of advanced ovarian carcinoma and its impact on level of serum CD133 and DDX4

Objective:To evaluate the effect of DC-CIK immune-cell therapy combined with chemotherapy on treatment of advanced ovarian carcinoma and its impact on level of serum CD133 and DDX4.Methods:60 patients with advanced ovarian carcinoma were randomly divided into experimental group (30 cases) and control group (30 cases).Patients in observation group were given DC-CIK immune-cell therapy combined with chemotherapy,and patients in control group were treated only by chemotherapy.The immune function,therapeutic effect,adverse reaction and the change of serum CD133 and DDX4 level of patients before and after treatment were recorded and compared between the two groups.Results:The objective response rate (ORR) of patients in observation group was 80.00 ％,which was significant higher than that of patients in control group (50.00％).After treatment and at six months followed-up,the level of CD3 +,CD3+CD4+,CD4+/CD8+ and NK cell of patients in observation group were significant higher than those of the patients in control group.The level of CD4+/CD25+,CD133,DDX4 of patients in observation group were significant lower than those of patients in control group.The level of CD3+CD4+,CD4+/CD8+ and NK cell of patients after treatment in observation group had increased,and the level of CD133,DDX4 of patients after treatment in observation group had declined(P＜0.05),but there was no statistically significant differences in indicators of immune function of patients in observation group after treatment (P＞0.05).The incidence of bone marrow suppression and liver damage of patients in experimental group were significant lower than those of patients in control group (P＜0.05).Conclusion:Patient with advanced ovarian carcinoma treated by DC-CIK immune-cell combined with chemotherapy can improve the clinical therapeutic effect,promote the immune function,decline serum CD133 and DDX4 level,as well as decrease the incidence of adverse reactions.It's worthy of clinical application.